NCT06389006招募中2 期
A Single-arm, Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 79
- 试验地点
- 1
- 主要终点
- Total pathological complete response (tpCR) rate
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer
详细描述
This is a single-arm, open-label, multicenter phase II clinical trial to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as neoadjuvant treatment in patients with HR-positive, HER2-low breast cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily agree to participate in the study and sign the informed consent;
- •Age ≥18 years old (including the threshold value);
- •Histologically confirmed invasive breast cancer with clinical stage T1c-T2(≥2cm)cN1-2M0 or T3cN0-2M0;
- •As assessed by the research Center, the subjects can tolerate and plan to undergo radical surgery for breast cancer and have not previously received any anti-tumor systemic therapy for breast cancer;
- •Invasive breast tumor tissue with low HER2 expression confirmed by the central laboratory is defined as IHC 1+ or IHC 2+ expression of HER2 protein detected by immunohistochemistry (IHC), and no amplification detected by in situ hybridization (ISH) (according to the Breast Cancer HER2 Detection Guidelines 2019); Primary tumor specimens (wax pieces, slices or fresh tissues) can be provided for HER2 detection;
- •According to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2020 guidelines, tumor tissue estrogen receptor (ER) and progesterone receptor (PgR) expression ≥ 1%;
- •Histological grade (Nottingham grading system) G3 or G2 with ER expression
- •ECOG physical status 0 or 1;
- •At least one measurable lesion according to RECIST v1.1 standard;
- •Heart function:
- •New York Heart Association (NYHA) Grade < 3;
- •left ventricular ejection fraction ≥50%;
- •Bone marrow or organ function should meet the following criteria within 7 days before the study dose:
- •Hemoglobin ≥ 90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet ≥ 100 ×109/L; Serum total bilirubin ≤ 1.5 times the upper limit of normal value (ULN); Aspartate aminotransferase (AST) and glutamic pyruvic transaminase (ALT) ≤ 2.5 times the upper limit of normal value; International normalized ratio (INR) and activated partial thrombin time ≤ 1.5×ULN; Serum creatinine ≤ 1.5×ULN or creatinine clearance (CrCl) ≥ 50 mL/min according to Cockcroft-Gault formula method;
- •Fertile female subjects who meet the following conditions
- •A serum pregnancy test (minimum sensitivity 25 mIU/mL or equivalent units of β-human chorionic gonadotropin [β-hCG]) must be negative within 72 hours before the first dosing of the study intervention. Subjects with false positive results who are confirmed not to be pregnant are eligible for study.
- •Must agree to contraception for the duration of the study and for at least 6 months after the last dose of investigational drug.
- •Must agree not to breastfeed or donate eggs from the time of signing the informed consent until 6 months after the last dose of investigational drug.
- •If sexually active and likely to result in pregnancy, continuous use of at least 2 acceptable forms of contraception, at least 1 of which must be highly effective from the time of the informed consent and continue until at least 6 months after the last dosing of the investigational drug.
- •Fertile male subjects who meet the following conditions
- •Must agree not to donate sperm from the time of signing the informed consent until at least 4 months after the last dose of investigational drug.
- •If sexual activity with a fertile person is likely to result in pregnancy, continuous use of at least 2 acceptable forms of contraception, at least 1 of which must be highly effective from the time of the informed consent and continue until at least 4 months after the last dosing of the investigational drug.
- •If sexually active with a pregnant or breastfeeding patient, condom use must continue from informed consent until at least 4 months after the last dosing of the investigational drug.
- •Able to understand trial requirements, willing and able to follow trial and follow-up procedures.
排除标准
- •Bilateral invasive breast cancer;
- •Previous history of invasive breast cancer;
- •Previously had carcinoma in situ of the breast and received adjuvant endocrine therapy within 5 years of surgery;
- •Use of the investigational drug or major surgery within 4 weeks prior to study dosing;
- •Have received or plan to receive live or attenuated vaccine within 4 weeks before the start of study dose;
- •Previous history of receiving allogeneic hematopoietic stem cell transplantation or organ transplantation;
- •Previous treatment with PD-(L)1, PD-L2, CTLA4 inhibitors and other Antibody-Drug Conjugates;
- •Uncontrolled or significant cardiovascular and cerebrovascular diseases
- •Presence of other treatable or serious lung diseases, including but not limited to active tuberculosis, interstitial lung disease, etc.;
- •Suffering from an active infection that requires systematic treatment;
- •Have active autoimmune diseases requiring systemic treatment within the past 2 years, allowing for relevant replacement therapy;
- •Have a clear past or present history of neurological or psychiatric disorders, including epilepsy or dementia;
- •Persistent ≥ grade 2 sensory or motor neuropathy;
- •In the judgment of the investigator, there is a serious concomitant disease that endangers the safety of the subject or interferes with the completion of the clinical study;
- •Positive HIV test result; Patients with active hepatitis B or C; Persistent coronavirus (COVID-19) infection;
- •Known hypersensitivity or delayed anaphylaxis to certain components of Disitamab Vedotin, and Toripalimab or Certain components of chemotherapy drugs or similar drugs used in the study;
- •Suffering from another malignancy within 5 years prior to signing the informed consent
研究组 & 干预措施
Disitamab Vedotin combined with Toripalimab sequential chemotherapy（Epirubicin +CTX）
Experimental
Disitamab Vedotin combined with Toripalimab sequential chemotherapy arm
干预措施: Disitamab Vedotin for Injection (Drug)
Disitamab Vedotin combined with Toripalimab sequential chemotherapy（Epirubicin +CTX）
Experimental
Disitamab Vedotin combined with Toripalimab sequential chemotherapy arm
干预措施: Toripalimab (Drug)
Disitamab Vedotin combined with Toripalimab sequential chemotherapy（Epirubicin +CTX）
Experimental
Disitamab Vedotin combined with Toripalimab sequential chemotherapy arm
干预措施: Epirubicin (Drug)
Disitamab Vedotin combined with Toripalimab sequential chemotherapy（Epirubicin +CTX）
Experimental
Disitamab Vedotin combined with Toripalimab sequential chemotherapy arm
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
Total pathological complete response (tpCR) rate
时间窗: 1month after surgery
Defined as the proportion of participants with a pathological assessment of pCR (ypT0/Tis, ypN0) in the analyzed population
次要结局
- Objective Response Rate (ORR)(Baseline to surgery)
- Health-related quality of life - EORTC-QLQ-C30(Up to approximately 2 years)
- Breast pathological complete response（bpCR）(1 month after surgery)
- Residual cancer burden score(1 month after surgery)
- Change in tumor-infiltrating lymphocytes (TILs)(At baseline to surgery)
- Change in programmed cell death protein L1 (PD-L1)(At baseline to surgery)
- Event free survival (EFS)(Up to approximately 3 or 5 years)
- Disease-free survival (DFS)(Up to approximately 3 or 5 years)
- Adverse events (AEs)(Up to approximately 2 months after surgery)
- Change in cluster of differentiation 8 (CD8)(At baseline to surgery)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyGastroesophageal Junction AdenocarcinomaGastric CancerNCT06221748RemeGen Co., Ltd.90
招募中
1 期
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric CancerHER2-low-expressing Gastric CancerGastric CancerNCT06078982Shanghai East Hospital39
招募中
2 期
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerBreast CancerNCT06178159RemeGen Co., Ltd.40
招募中
2 期
Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableHer2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNCT05495724Tianjin Medical University Second Hospital176
招募中
2 期
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerCastration-resistant Prostate CancerNCT06227156RemeGen Co., Ltd.40